Comparative Pharmacology
Head-to-head clinical analysis: CYSTOGRAFIN versus CYSTOGRAFIN DILUTE.
Head-to-head clinical analysis: CYSTOGRAFIN versus CYSTOGRAFIN DILUTE.
CYSTOGRAFIN vs CYSTOGRAFIN DILUTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cystografin is an ionic, water-soluble, iodinated radiographic contrast agent. It contains diatrizoate meglumine and diatrizoate sodium. Iodine atoms absorb X-rays, providing enhanced contrast in imaging studies. It is administered into body cavities for visualization.
Cystografin dilute is a radiocontrast agent containing diatrizoate meglumine, which is an ionic monomeric iodinated compound. It provides radiopacity by absorbing X-rays due to the high atomic number of iodine, allowing visualization of the urinary tract during retrograde cystourethrography. The mechanism is purely physical, with no pharmacological effect.
Intravesical instillation: 300-500 mL of 30% solution via urethral catheter for cystography; Intravenous: 0.5-1.0 mL/kg of 30-60% solution for urography, maximum 100 mL.
Instill 200-300 mL of CYSTOGRAFIN DILUTE (17.2% iodine) via bladder catheter for retrograde cystography. For intraoperative cholangiography, instill 10-25 mL via cystic duct catheter. For voiding cystourethrography (VCUG), fill bladder to capacity (typically 300-500 mL in adults) under gravity until voiding occurs.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours in patients with normal renal function; prolonged in renal impairment (up to 30+ hours in severe impairment).
Terminal elimination half-life: 1–2 hours in normal renal function; prolonged in renal impairment (up to 20–30 hours in severe renal failure)
Renal excretion of unchanged drug via glomerular filtration; >95% eliminated in urine within 24 hours. Less than 5% biliary/fecal.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Iodinated Contrast Agent
Iodinated Contrast Agent